person · Reporting owner

GADICKE ANSBERT

Disclosed activity across 13 companies

Tapewire entity: 2481
SEC CIK: 0001134655

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aktis Oncology, Inc.AKTS · Entity 4711	10% owner	January 12, 2026	January 14, 2026
Cullinan Therapeutics, Inc.CGEM · Entity 4766	10% owner · Former Director	December 31, 2021	February 10, 2023
Dyne Therapeutics, Inc.DYN · Entity 3948	10% owner	September 21, 2020	September 23, 2020
Harpoon Therapeutics, Inc.HARP · Entity 11424	10% owner	May 28, 2021	June 02, 2021
Kalaris Therapeutics, Inc.ALVR · Entity 6805	Director · 10% owner	July 28, 2022	August 01, 2022
Oncorus, Inc.ONCR · Entity 112213	10% owner	October 06, 2020	October 08, 2020
RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693	10% owner	October 10, 2017	October 11, 2017
Radius Health, Inc.RDUS · Entity 124173	Director	February 17, 2017	February 22, 2017
Repare Therapeutics Inc.RPTX · Entity 68433	10% owner	July 09, 2021	July 13, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aktis Oncology, Inc.

Report date January 12, 2026 · Filed January 14, 2026

Jointly reported with MPM ASSET MANAGEMENT LLC, Oncology Impact Private Investment Fund 2, L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,655,971	Reported balance After 2026-01-12 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2026-01-12 · Conversion · Acquired 1,314,262 · Balance 1,655,971 F1: The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"), 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"), 119,478 by MPM Oncology Innovations Fund, L.P. ("MPM Oncology") and 597,393 by Oncology Impact Private Investment Fund 2, L.P. ("MPM Oncology Impact"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Drs. Evnin and Gadicke are managing directors of BV 2018 LLC and managers of MPM Oncology Innovations Fund GP LLC, which is the general partner of MPM Oncology. Dr. Gadicke is the managing member of MPM Oncology Investments 2 LLC, which is the general partner of MPM Oncology Impact. F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4: The shares are held as follows: 341,709 by MPM Asset Management LLC ("MPM AM"), 556,810 by BV 2018, 29,593 by BV 2018(B), 10,988 by AM BV2018, 119,478 by MPM Oncology and 597,393 by MPM Oncology Impact. Dr. Gadicke is the manager of MPM AM.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	7,570,168	Reported balance After 2026-01-12 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2026-01-12 · Conversion · Acquired 5,914,197 · Balance 7,570,168 F5: The shares of common stock were issued upon conversion as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B), 49,452 by AM BV2018, 537,654 by MPM Oncology and 2,688,273 by MPM Oncology Impact. F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F6: The shares are held as follows: 341,709 by MPM AM, 3,062,458 by BV 2018, 162,763 by BV 2018(B), 60,440 by AM BV2018, 657,132 by MPM Oncology and 3,285,666 by MPM Oncology Impact.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	9,147,287	Reported balance After 2026-01-12 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2026-01-12 · Conversion · Acquired 1,577,119 · Balance 9,147,287 F7: The shares of common stock were issued upon conversion as follows: 668,173 by BV 2018, 35,512 by BV 2018(B), 13,187 by AM BV2018, 143,374 by MPM Oncology and 716,873 by MPM Oncology Impact. F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8: The shares are held as follows: 341,709 by MPM AM, 3,730,631 by BV 2018, 198,275 by BV 2018(B), 73,627 by AM BV2018, 800,506 by MPM Oncology and 4,002,539 by MPM Oncology Impact.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	10,260,064	Reported balance After 2026-01-12 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2026-01-12 · Purchase · Acquired 1,112,777 · Balance 10,260,064 F9: The shares were purchased as follows: 219,897 by BV 2018, 8,689 by BV 2018(B), 4,284 by AM BV2018, 46,574 by MPM Oncology and 833,333 by MPM Oncology Impact. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F10: The shares are held as follows: 341,709 by MPM AM, 3,950,528 by BV 2018, 206,964 by BV 2018(B), 77,911 by AM BV2018, 847,080 by MPM Oncology and 4,835,872 by MPM Oncology Impact.
Series Seed Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-01-12 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-01-12 · Conversion · Disposed 5,000,000 · Balance 0 F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F1: The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"), 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"), 119,478 by MPM Oncology Innovations Fund, L.P. ("MPM Oncology") and 597,393 by Oncology Impact Private Investment Fund 2, L.P. ("MPM Oncology Impact"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Drs. Evnin and Gadicke are managing directors of BV 2018 LLC and managers of MPM Oncology Innovations Fund GP LLC, which is the general partner of MPM Oncology. Dr. Gadicke is the managing member of MPM Oncology Investments 2 LLC, which is the general partner of MPM Oncology Impact. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-01-12 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-01-12 · Conversion · Disposed 22,500,000 · Balance 0 F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5: The shares of common stock were issued upon conversion as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B), 49,452 by AM BV2018, 537,654 by MPM Oncology and 2,688,273 by MPM Oncology Impact.
Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-01-12 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-01-12 · Conversion · Disposed 6,000,000 · Balance 0 F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F7: The shares of common stock were issued upon conversion as follows: 668,173 by BV 2018, 35,512 by BV 2018(B), 13,187 by AM BV2018, 143,374 by MPM Oncology and 716,873 by MPM Oncology Impact.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"), 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"), 119,478 by MPM Oncology Innovations Fund, L.P. ("MPM Oncology") and 597,393 by Oncology Impact Private Investment Fund 2, L.P. ("MPM Oncology Impact"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Drs. Evnin and Gadicke are managing directors of BV 2018 LLC and managers of MPM Oncology Innovations Fund GP LLC, which is the general partner of MPM Oncology. Dr. Gadicke is the managing member of MPM Oncology Investments 2 LLC, which is the general partner of MPM Oncology Impact.

F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date.

F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F4: The shares are held as follows: 341,709 by MPM Asset Management LLC ("MPM AM"), 556,810 by BV 2018, 29,593 by BV 2018(B), 10,988 by AM BV2018, 119,478 by MPM Oncology and 597,393 by MPM Oncology Impact. Dr. Gadicke is the manager of MPM AM.

F5: The shares of common stock were issued upon conversion as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B), 49,452 by AM BV2018, 537,654 by MPM Oncology and 2,688,273 by MPM Oncology Impact.

F6: The shares are held as follows: 341,709 by MPM AM, 3,062,458 by BV 2018, 162,763 by BV 2018(B), 60,440 by AM BV2018, 657,132 by MPM Oncology and 3,285,666 by MPM Oncology Impact.

F7: The shares of common stock were issued upon conversion as follows: 668,173 by BV 2018, 35,512 by BV 2018(B), 13,187 by AM BV2018, 143,374 by MPM Oncology and 716,873 by MPM Oncology Impact.

F8: The shares are held as follows: 341,709 by MPM AM, 3,730,631 by BV 2018, 198,275 by BV 2018(B), 73,627 by AM BV2018, 800,506 by MPM Oncology and 4,002,539 by MPM Oncology Impact.

F9: The shares were purchased as follows: 219,897 by BV 2018, 8,689 by BV 2018(B), 4,284 by AM BV2018, 46,574 by MPM Oncology and 833,333 by MPM Oncology Impact.

F10: The shares are held as follows: 341,709 by MPM AM, 3,950,528 by BV 2018, 206,964 by BV 2018(B), 77,911 by AM BV2018, 847,080 by MPM Oncology and 4,835,872 by MPM Oncology Impact.

Cullinan Therapeutics, Inc.

Report date December 31, 2021 · Filed February 10, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	595,489	Reported balance After 2021-12-21 transaction · row 1 1 source row Row 1 · 2021-12-21 · Exercise / conversion · Acquired 350,938 · Balance 595,489
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.30 · Expires 2030-10-28	Direct	0	Reported balance After 2021-12-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-12-21 · Exercise / conversion · Disposed 262,114 · Balance 0 F3: These options are fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.30 · Expires 2030-10-28	Direct	0	Reported balance After 2021-12-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-12-21 · Exercise / conversion · Disposed 88,824 · Balance 0 F3: These options are fully vested.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	7,648,268	Reported balance Holding disclosure · report date 2021-12-31 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 7,648,268 F1: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC.

F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F3: These options are fully vested.

Dyne Therapeutics, Inc.

Report date September 21, 2020 · Filed September 23, 2020

Jointly reported with MPM BIOVENTURES 2018, L.P., MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC, MPM BioVentures 2018 GP LLC, MPM BioVentures 2018 LLC, EVNIN LUKE, Foley Todd

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	4,614,943	Reported balance After 2020-09-21 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-09-21 · Conversion · Acquired 4,614,943 · Balance 4,614,943 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The shares are held directly by MPM BioVentures 2018, L.P. ("BV 2018"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC ("BV 2018 GP"). MPM BioVentures 2018 LLC ("BV 2018 LLC") is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of its pecuniary interest therein, if any.
Common StockSEC Table I · non-derivative	IndirectSee footnote	245,279	Reported balance After 2020-09-21 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2020-09-21 · Conversion · Acquired 245,279 · Balance 245,279 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The shares are held directly by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of its pecuniary interest therein, if any.
Common StockSEC Table I · non-derivative	IndirectSee footnote	91,081	Reported balance After 2020-09-21 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2020-09-21 · Conversion · Acquired 91,081 · Balance 91,081 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4: The shares are held directly by MPM Asset Management Investors BV2018 LLC ("MPM Asset Management"). The manager of MPM Asset Management is BV 2018 LLC. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV2018 LLC. Each of BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-09-21 · Conversion · Disposed 13,980,992 · Balance 0 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The shares are held directly by MPM BioVentures 2018, L.P. ("BV 2018"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC ("BV 2018 GP"). MPM BioVentures 2018 LLC ("BV 2018 LLC") is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of its pecuniary interest therein, if any.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-21 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-09-21 · Conversion · Disposed 743,076 · Balance 0 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The shares are held directly by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of its pecuniary interest therein, if any.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-21 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-09-21 · Conversion · Disposed 275,932 · Balance 0 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4: The shares are held directly by MPM Asset Management Investors BV2018 LLC ("MPM Asset Management"). The manager of MPM Asset Management is BV 2018 LLC. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV2018 LLC. Each of BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-21 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-09-21 · Conversion · Disposed 1,326,313 · Balance 0 F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The shares are held directly by MPM BioVentures 2018, L.P. ("BV 2018"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC ("BV 2018 GP"). MPM BioVentures 2018 LLC ("BV 2018 LLC") is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of its pecuniary interest therein, if any.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-21 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-09-21 · Conversion · Disposed 70,492 · Balance 0 F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The shares are held directly by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of its pecuniary interest therein, if any.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-21 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-09-21 · Conversion · Disposed 26,176 · Balance 0 F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4: The shares are held directly by MPM Asset Management Investors BV2018 LLC ("MPM Asset Management"). The manager of MPM Asset Management is BV 2018 LLC. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV2018 LLC. Each of BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F2: The shares are held directly by MPM BioVentures 2018, L.P. ("BV 2018"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC ("BV 2018 GP"). MPM BioVentures 2018 LLC ("BV 2018 LLC") is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of its pecuniary interest therein, if any.

F3: The shares are held directly by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of its pecuniary interest therein, if any.

F4: The shares are held directly by MPM Asset Management Investors BV2018 LLC ("MPM Asset Management"). The manager of MPM Asset Management is BV 2018 LLC. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV2018 LLC. Each of BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any.

F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

Harpoon Therapeutics, Inc.

Report date May 28, 2021 · Filed June 02, 2021

Jointly reported with Oncology Impact Fund (Cayman) Management L.P., MPM BIOIMPACT LLC, MPM Oncology Impact Management GP LLC, UBS Oncology Impact Fund L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	6,374,904	Reported balance After 2021-05-28 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-05-28 · Sale · Disposed 10,685 · Balance 6,374,904 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F2: The shares were sold as follows: 9,392 by UBS Oncology Impact Fund, L.P. ("UBS Oncology") and 1,293 by MPM Asset Management LLC ("AM LLC"). F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.52 to $21.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 231,110 by AM LLC and 3,237,851 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	6,371,804	Reported balance After 2021-05-28 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2021-05-28 · Sale · Disposed 3,100 · Balance 6,371,804 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F5: The shares were sold as follows: 2,725 by UBS Oncology and 375 by AM LLC. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.58 to $22.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 230,735 by AM LLC and 3,235,126 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	6,371,704	Reported balance After 2021-05-28 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2021-05-28 · Sale · Disposed 100 · Balance 6,371,704 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F8: The shares were sold as follows: 88 by UBS Oncology and 12 by AM LLC. F9: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 230,723 by AM LLC and 3,235,038 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	6,353,213	Reported balance After 2021-06-01 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2021-06-01 · Sale · Disposed 18,491 · Balance 6,353,213 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F10: The shares were sold as follows: 16,253 by UBS Oncology and 2,238 by AM LLC. F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F12: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 228,485 by AM LLC and 3,218,785 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	6,328,095	Reported balance After 2021-06-02 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2021-06-02 · Sale · Disposed 25,118 · Balance 6,328,095 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F13: The shares were sold as follows: 22,078 by UBS Oncology and 3,040 by AM LLC. F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.24 to $20.76 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F15: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 225,445 by AM LLC and 3,196,707 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021.

F2: The shares were sold as follows: 9,392 by UBS Oncology Impact Fund, L.P. ("UBS Oncology") and 1,293 by MPM Asset Management LLC ("AM LLC").

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.52 to $21.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 231,110 by AM LLC and 3,237,851 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F5: The shares were sold as follows: 2,725 by UBS Oncology and 375 by AM LLC.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.58 to $22.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 230,735 by AM LLC and 3,235,126 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F8: The shares were sold as follows: 88 by UBS Oncology and 12 by AM LLC.

F9: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 230,723 by AM LLC and 3,235,038 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F10: The shares were sold as follows: 16,253 by UBS Oncology and 2,238 by AM LLC.

F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F12: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 228,485 by AM LLC and 3,218,785 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F13: The shares were sold as follows: 22,078 by UBS Oncology and 3,040 by AM LLC.

F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.24 to $20.76 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F15: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 225,445 by AM LLC and 3,196,707 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

Kalaris Therapeutics, Inc.

Report date July 28, 2022 · Filed August 01, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy ElevateBio LLC	16,674,766	Reported balance After 2022-07-28 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2022-07-28 · Grant · Acquired 3,253,796 · Balance 16,674,766 F1: On July 28, 2022, ElevateBio LLC ("ElevateBio") acquired 3,253,796 shares of the Issuer's Common Stock in a registered direct offering for a purchase price of $4.61 per share. F2: Shares held by ElevateBio. The Reporting Person is a director of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	Direct	30,197	Reported balance Holding disclosure · report date 2022-07-28 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 30,197

Filing footnotes · ownership attribution and instrument terms

F1: On July 28, 2022, ElevateBio LLC ("ElevateBio") acquired 3,253,796 shares of the Issuer's Common Stock in a registered direct offering for a purchase price of $4.61 per share.

F2: Shares held by ElevateBio. The Reporting Person is a director of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Oncorus, Inc.

Report date October 06, 2020 · Filed October 08, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,899,702	Reported balance After 2020-10-06 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2020-10-06 · Conversion · Acquired 1,783,879 · Balance 1,899,702 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F3: The shares are held as follows: 1,382,943 by MPM BioVentures 2014, L.P. ("BV 2014"), 92,239 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 50,164 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 224,924 by MPM Sunstates Fund, L.P. ("MPM SunStates"), 33,609 by MPM Asset Management Investors Sunstates Fund LLC ("AM SunStates") and 115,823 by MPM Asset Management LLC ("AM LLC"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM SunStates Fund GP LLC and MPM SunStates GP Managing Member LLC ("SunStates GP") are the direct and indirect general partners of MPM SunStates. SunStates GP is the manager of AM SunStates. Luke Evnin, Ansbert Gadicke and Todd Foley are the managing directors of BV LLC, Luke Evnin and Anbsert Gadicke are the members of AM LLC and Ansbert Gadicke is a member of SunStates GP.
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,525,348	Reported balance After 2020-10-06 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2020-10-06 · Conversion · Acquired 1,525,348 · Balance 1,525,348 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC.
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,675,677	Reported balance After 2020-10-06 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2020-10-06 · Conversion · Acquired 775,975 · Balance 2,675,677 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5: The shares are held as follows: 2,018,001 by BV 2014, 134,595 by BV 2014(B), 73,199 by AM BV2014, 290,632 by MPM SunStates, 43,427 by AM SunStates and 115,823 by AM LLC.
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,225,801	Reported balance After 2020-10-06 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2020-10-06 · Conversion · Acquired 700,453 · Balance 2,225,801 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC.
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,849,453	Reported balance After 2020-10-06 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2020-10-06 · Purchase · Acquired 173,776 · Balance 2,849,453 F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F6: The shares are held as follows: 2,155,108 by BV 2014, 143,740 by BV 2014(B), 78,172 by AM BV2014, 310,251 by MPM SunStates, 46,359 by AM SunStates and 115,823 by AM LLC.
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,377,025	Reported balance After 2020-10-06 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 6 · 2020-10-06 · Purchase · Acquired 151,224 · Balance 2,377,025 F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC.
Series A-1 Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-10-06 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-10-06 · Conversion · Acquired 1,783,879 · Balance 0 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F7: The shares are held as follows: 1,382,943 by BV 2014, 92,239 by BV 2014(B), 50,164 by AM BV2014, 224,924 by MPM SunStates and 33,609 by AM SunStates.
Series A-1 Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-10-06 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-10-06 · Conversion · Acquired 1,525,348 · Balance 0 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-10-06 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-10-06 · Conversion · Acquired 775,975 · Balance 0 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8: The shares are held as follows: 635,058 by BV 2014, 42,356 by BV 2014(B), 23,035 by AM BV2014, 65,708 by MPM SunStates and 9,818 by AM SunStates.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-10-06 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2020-10-06 · Conversion · Acquired 700,453 · Balance 0 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date.

F2: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F3: The shares are held as follows: 1,382,943 by MPM BioVentures 2014, L.P. ("BV 2014"), 92,239 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 50,164 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 224,924 by MPM Sunstates Fund, L.P. ("MPM SunStates"), 33,609 by MPM Asset Management Investors Sunstates Fund LLC ("AM SunStates") and 115,823 by MPM Asset Management LLC ("AM LLC"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM SunStates Fund GP LLC and MPM SunStates GP Managing Member LLC ("SunStates GP") are the direct and indirect general partners of MPM SunStates. SunStates GP is the manager of AM SunStates. Luke Evnin, Ansbert Gadicke and Todd Foley are the managing directors of BV LLC, Luke Evnin and Anbsert Gadicke are the members of AM LLC and Ansbert Gadicke is a member of SunStates GP.

F4: The reported securities are held in the account of UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC.

F5: The shares are held as follows: 2,018,001 by BV 2014, 134,595 by BV 2014(B), 73,199 by AM BV2014, 290,632 by MPM SunStates, 43,427 by AM SunStates and 115,823 by AM LLC.

F6: The shares are held as follows: 2,155,108 by BV 2014, 143,740 by BV 2014(B), 78,172 by AM BV2014, 310,251 by MPM SunStates, 46,359 by AM SunStates and 115,823 by AM LLC.

F7: The shares are held as follows: 1,382,943 by BV 2014, 92,239 by BV 2014(B), 50,164 by AM BV2014, 224,924 by MPM SunStates and 33,609 by AM SunStates.

F8: The shares are held as follows: 635,058 by BV 2014, 42,356 by BV 2014(B), 23,035 by AM BV2014, 65,708 by MPM SunStates and 9,818 by AM SunStates.

RHYTHM PHARMACEUTICALS, INC.

Report date October 10, 2017 · Filed October 11, 2017

Jointly reported with MPM BIOVENTURES V, L.P., EVNIN LUKE, MPM ASSET MANAGEMENT INVESTORS BV5 LLC, MPM BIOVENTURES V GP LLC, MPM BIOVENTURES V LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	2,596,392	Reported balance After 2017-10-10 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2017-10-10 · Conversion · Acquired 2,567,014 · Balance 2,596,392 F1: Each share of preferred stock converted into approximately 0.10905125 shares of common stock upon the closing of the issuer's initial public offering. The shares had no expiration date. F2: The shares are held as follows: 2,499,299 by MPM BioVentures V, L.P. ("BV V") and 97,093 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. Mr. Foley is a director of the Issuer and has separately filed a Form 4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	2,696,392	Reported balance After 2017-10-10 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2017-10-10 · Purchase · Acquired 100,000 · Balance 2,696,392 F3: Shares were purchased as follows: 96,260 by BV V and 3,740 by AM BV5. F4: Shares are held as follows: 2,595,559 by BV V and 100,833 by AM BV5. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2017-10-10 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-10-10 · Conversion · Disposed 7,651,831 · Balance 0 F1: Each share of preferred stock converted into approximately 0.10905125 shares of common stock upon the closing of the issuer's initial public offering. The shares had no expiration date. F5: The shares of Series A Preferred Stock were held as follows: 7,365,688 by BV V and 286,143 by AM BV5.
Series A-1 Junior Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2017-10-10 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-10-10 · Conversion · Disposed 15,887,703 · Balance 0 F1: Each share of preferred stock converted into approximately 0.10905125 shares of common stock upon the closing of the issuer's initial public offering. The shares had no expiration date. F6: The shares of Series A-1 Junior Preferred Stock were held as follows: 15,293,569 by BV V and 594,134 by AM BV5.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of preferred stock converted into approximately 0.10905125 shares of common stock upon the closing of the issuer's initial public offering. The shares had no expiration date.

F2: The shares are held as follows: 2,499,299 by MPM BioVentures V, L.P. ("BV V") and 97,093 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. Mr. Foley is a director of the Issuer and has separately filed a Form 4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

F3: Shares were purchased as follows: 96,260 by BV V and 3,740 by AM BV5.

F4: Shares are held as follows: 2,595,559 by BV V and 100,833 by AM BV5. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

F5: The shares of Series A Preferred Stock were held as follows: 7,365,688 by BV V and 286,143 by AM BV5.

F6: The shares of Series A-1 Junior Preferred Stock were held as follows: 15,293,569 by BV V and 594,134 by AM BV5.

Radius Health, Inc.

Report date February 17, 2017 · Filed February 22, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.65 · Expires 2027-02-16	Direct	27,500	Reported balance After 2017-02-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-02-17 · Grant · Acquired 27,500 · Balance 27,500 F1: The option vests in full on February 17, 2018, subject to continued service to the Issuer through such date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in full on February 17, 2018, subject to continued service to the Issuer through such date.

Repare Therapeutics Inc.

Report date July 09, 2021 · Filed July 13, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	IndirectSee Footnote	3,940,497	Reported balance After 2021-07-09 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2021-07-09 · Sale · Disposed 4,067 · Balance 3,940,497 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F2: The shares were sold as follows: 1,732 by MPM BioVentures 2014, L.P. ("BV 2014"), 60 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 2,275 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.95 to $33.20 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: The shares are held as follows: 2,061,400 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 70,952 by AM BV2014 and 1,672,302 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Ansbert Gadicke is a managing director of BV LLC. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the Managing Member of Oncology GP LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
Common SharesSEC Table I · non-derivative	IndirectSee Footnote	3,883,196	Reported balance After 2021-07-12 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2021-07-12 · Sale · Disposed 57,301 · Balance 3,883,196 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F5: The shares were sold as follows: 24,408 by BV 2014, 838 by AM BV2014 and 32,055 by UBS Oncology. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.05 to $34.04 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7: The shares are held as follows: 2,036,992 by BV 2014, 135,843 by BV 2014(B), 70,114 by AM BV2014 and 1,640,247 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
Common SharesSEC Table I · non-derivative	IndirectSee Footnote	3,882,485	Reported balance After 2021-07-12 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2021-07-12 · Sale · Disposed 711 · Balance 3,882,485 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F8: The shares were sold as follows: 303 by BV 2014, 10 by AM BV2014 and 398 by UBS Oncology. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.055 to $34.135 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F10: The shares are held as follows: 2,036,689 by BV 2014, 135,843 by BV 2014(B), 70,104 by AM BV2014 and 1,639,849 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021.

F2: The shares were sold as follows: 1,732 by MPM BioVentures 2014, L.P. ("BV 2014"), 60 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 2,275 by UBS Oncology Impact Fund L.P. ("UBS Oncology").

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.95 to $33.20 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The shares are held as follows: 2,061,400 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 70,952 by AM BV2014 and 1,672,302 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Ansbert Gadicke is a managing director of BV LLC. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the Managing Member of Oncology GP LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F5: The shares were sold as follows: 24,408 by BV 2014, 838 by AM BV2014 and 32,055 by UBS Oncology.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.05 to $34.04 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7: The shares are held as follows: 2,036,992 by BV 2014, 135,843 by BV 2014(B), 70,114 by AM BV2014 and 1,640,247 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F8: The shares were sold as follows: 303 by BV 2014, 10 by AM BV2014 and 398 by UBS Oncology.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.055 to $34.135 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F10: The shares are held as follows: 2,036,689 by BV 2014, 135,843 by BV 2014(B), 70,104 by AM BV2014 and 1,639,849 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Entrada Therapeutics, Inc.

Report date September 04, 2026 · Filed September 09, 2026

Jointly reported with MPM BioVentures 2014, L.P., EVNIN LUKE, Foley Todd, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC

Section 16 reporting ended · disclosed 2026-09-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	4,106,452	Reported balance After 2026-09-04 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2026-09-04 · Sale · Disposed 38,500 · Balance 4,106,452 F1: The shares were sold as follows: 17,482 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,166 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 602 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 17,942 by MPM BioVentures 2018, L.P. ("BV 2018"), 954 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 354 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC. F2: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.01 to $7.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3: The shares are held as follows: 1,864,673 by BV 2014, 124,370 by BV 2014(B), 64,182 by AM BV2014, 1,913,743 by BV 2018, 101,714 by BV 2018(B) and 37,770 by AM BV2018. F4: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,913,952	Reported balance After 2026-09-08 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2026-09-08 · Sale · Disposed 192,500 · Balance 3,913,952 F5: The shares were sold as follows: 87,411 by BV 2014, 5,830 by BV 2014(B), 3,009 by AM BV2014, 89,712 by BV 2018, 4,768 by BV 2018(B) and 1,770 by AM BV2018. F6: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F7: The shares are held as follows: 1,777,262 by BV 2014, 118,540 by BV 2014(B), 61,173 by AM BV2014, 1,824,031 by BV 2018, 96,946 by BV 2018(B) and 36,000 by AM BV2018.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,885,115	Reported balance After 2026-09-09 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2026-09-09 · Sale · Disposed 28,837 · Balance 3,885,115 F8: The shares were sold as follows: 13,095 by BV 2014, 873 by BV 2014(B), 451 by AM BV2014, 13,439 by BV 2018, 714 by BV 2018(B) and 265 by AM BV2018. F9: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.02 to $7.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F10: The shares are held as follows: 1,764,167 by BV 2014, 117,667 by BV 2014(B), 60,722 by AM BV2014, 1,810,592 by BV 2018, 96,232 by BV 2018(B) and 35,735 by AM BV2018.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were sold as follows: 17,482 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,166 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 602 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 17,942 by MPM BioVentures 2018, L.P. ("BV 2018"), 954 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 354 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.

F2: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.01 to $7.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

F3: The shares are held as follows: 1,864,673 by BV 2014, 124,370 by BV 2014(B), 64,182 by AM BV2014, 1,913,743 by BV 2018, 101,714 by BV 2018(B) and 37,770 by AM BV2018.

F4: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

F5: The shares were sold as follows: 87,411 by BV 2014, 5,830 by BV 2014(B), 3,009 by AM BV2014, 89,712 by BV 2018, 4,768 by BV 2018(B) and 1,770 by AM BV2018.

F6: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

F7: The shares are held as follows: 1,777,262 by BV 2014, 118,540 by BV 2014(B), 61,173 by AM BV2014, 1,824,031 by BV 2018, 96,946 by BV 2018(B) and 36,000 by AM BV2018.

F8: The shares were sold as follows: 13,095 by BV 2014, 873 by BV 2014(B), 451 by AM BV2014, 13,439 by BV 2018, 714 by BV 2018(B) and 265 by AM BV2018.

F9: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.02 to $7.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

F10: The shares are held as follows: 1,764,167 by BV 2014, 117,667 by BV 2014(B), 60,722 by AM BV2014, 1,810,592 by BV 2018, 96,232 by BV 2018(B) and 35,735 by AM BV2018.

TCR2 THERAPEUTICS INC.

Report date June 01, 2023 · Filed June 05, 2023

Section 16 reporting ended · disclosed 2023-06-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2023-06-01 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2023-06-01 · Other · Disposed 304,001 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). F3: The shares were held by MPM Asset Management LLC ("AM LLC"). The reporting person is a member of AM LLC and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2023-06-01 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2023-06-01 · Other · Disposed 3,854,963 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). F4: The shares were held as follows: 3,056,272 by MPM BioVentures 2014, L.P. ("BV 2014"), 203,846 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 110,859 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 421,070 by MPM SunStates Fund, L.P. ("MPM SunStates") and 62,916 by MPM Asset Management Investors Sunstates Fund LLC ("AM SunStates"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B) and BV LLC is the manager of AM BV2014. MPM SunStates Fund GP LLC and MPM SunStates GP Managing Member LLC ("SunStates GP") are the direct and indirect general partners of MPM SunStates and SunStates GP is the manager of AM SunStates. The reporting person is a managing director of BV LLC and a member of SunStates GP and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2023-06-01 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2023-06-01 · Other · Disposed 3,370,982 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). F5: The shares were held by UBS Oncology Impact Fund L.P. ("UBS Oncology"). BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. The reporting person is the managing partner of BioImpact and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time").

F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares").

F3: The shares were held by MPM Asset Management LLC ("AM LLC"). The reporting person is a member of AM LLC and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

F4: The shares were held as follows: 3,056,272 by MPM BioVentures 2014, L.P. ("BV 2014"), 203,846 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 110,859 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 421,070 by MPM SunStates Fund, L.P. ("MPM SunStates") and 62,916 by MPM Asset Management Investors Sunstates Fund LLC ("AM SunStates"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B) and BV LLC is the manager of AM BV2014. MPM SunStates Fund GP LLC and MPM SunStates GP Managing Member LLC ("SunStates GP") are the direct and indirect general partners of MPM SunStates and SunStates GP is the manager of AM SunStates. The reporting person is a managing director of BV LLC and a member of SunStates GP and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

F5: The shares were held by UBS Oncology Impact Fund L.P. ("UBS Oncology"). BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. The reporting person is the managing partner of BioImpact and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Werewolf Therapeutics, Inc.

Report date December 02, 2025 · Filed December 04, 2025

Jointly reported with MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BIOIMPACT LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC

Section 16 reporting ended · disclosed 2025-12-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	4,924,566	Reported balance After 2025-12-02 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-12-02 · Sale · Disposed 59,277 · Balance 4,924,566 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F2: The shares were sold as follows: 4,070 by MPM Asset Management LLC ("AM LLC"), 25,712 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,715 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 884 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 5,662 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 21,234 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.852 to $0.9246 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5: The shares are held as follows: 338,231 by AM LLC, 2,135,926 by BV 2014, 142,463 by BV 2014(B), 73,518 by AM BV2014, 468,282 by MPM OIF and 1,766,146 by UBS Oncology.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	4,867,341	Reported balance After 2025-12-03 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2025-12-03 · Sale · Disposed 57,225 · Balance 4,867,341 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F6: The shares were sold as follows: 3,929 by AM LLC, 24,821 by BV 2014, 1,656 by BV 2014(B), 854 by AM BV2014, 5,466 by MPM OIF and 20,499 by UBS Oncology. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.9256 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8: The shares are held as follows: 334,302 by AM LLC, 2,111,105 by BV 2014, 140,807 by BV 2014(B), 72,664 by AM BV2014, 462,816 by MPM OIF and 1,745,647 by UBS Oncology.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	4,784,111	Reported balance After 2025-12-04 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2025-12-04 · Sale · Disposed 83,230 · Balance 4,784,111 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. F9: The shares were sold as follows: 5,714 by AM LLC, 36,101 by BV 2014, 2,408 by BV 2014(B), 1,243 by AM BV2014, 7,950 by MPM OIF and 29,814 by UBS Oncology. F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $1.0208 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F11: The shares are held as follows: 328,588 by AM LLC, 2,075,004 by BV 2014, 138,399 by BV 2014(B), 71,421 by AM BV2014, 454,866 by MPM OIF and 1,715,833 by UBS Oncology.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.

F2: The shares were sold as follows: 4,070 by MPM Asset Management LLC ("AM LLC"), 25,712 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,715 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 884 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 5,662 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 21,234 by UBS Oncology Impact Fund L.P. ("UBS Oncology").

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.852 to $0.9246 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a manager of MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F5: The shares are held as follows: 338,231 by AM LLC, 2,135,926 by BV 2014, 142,463 by BV 2014(B), 73,518 by AM BV2014, 468,282 by MPM OIF and 1,766,146 by UBS Oncology.

F6: The shares were sold as follows: 3,929 by AM LLC, 24,821 by BV 2014, 1,656 by BV 2014(B), 854 by AM BV2014, 5,466 by MPM OIF and 20,499 by UBS Oncology.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.9256 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F8: The shares are held as follows: 334,302 by AM LLC, 2,111,105 by BV 2014, 140,807 by BV 2014(B), 72,664 by AM BV2014, 462,816 by MPM OIF and 1,745,647 by UBS Oncology.

F9: The shares were sold as follows: 5,714 by AM LLC, 36,101 by BV 2014, 2,408 by BV 2014(B), 1,243 by AM BV2014, 7,950 by MPM OIF and 29,814 by UBS Oncology.

F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $1.0208 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F11: The shares are held as follows: 328,588 by AM LLC, 2,075,004 by BV 2014, 138,399 by BV 2014(B), 71,421 by AM BV2014, 454,866 by MPM OIF and 1,715,833 by UBS Oncology.

iTeos Therapeutics, Inc.

Report date May 13, 2025 · Filed May 15, 2025

Jointly reported with MPM BIOIMPACT LLC, Oncology Impact Fund (Cayman) Management L.P., UBS Oncology Impact Fund L.P.

Section 16 reporting ended · disclosed 2025-05-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,452,797	Reported balance After 2025-05-13 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-05-13 · Sale · Disposed 1,031,931 · Balance 3,452,797 F1: The shares were sold as follows: 355,406 by MPM BioVentures 2014, L.P. ("BV 2014"), 22,386 by MPM BioVentures 2014 (B), L.P. ("BV 2014(B)"), 12,233 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 224,467 by MPM BioVentures 2018, L.P. ("BV 2018"), 11,267 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 4,432 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 401,740 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC. F2: MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.73 to $8.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: The shares are held as follows: 1,189,174 by BV 2014, 74,903 by BV 2014(B), 40,931 by AM BV2014, 751,056 by BV 2018, 37,699 by BV 2018(B), 14,831 by AM BV2018 and 1,344,203 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were sold as follows: 355,406 by MPM BioVentures 2014, L.P. ("BV 2014"), 22,386 by MPM BioVentures 2014 (B), L.P. ("BV 2014(B)"), 12,233 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 224,467 by MPM BioVentures 2018, L.P. ("BV 2018"), 11,267 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 4,432 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 401,740 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC.

F2: MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.73 to $8.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The shares are held as follows: 1,189,174 by BV 2014, 74,903 by BV 2014(B), 40,931 by AM BV2014, 751,056 by BV 2018, 37,699 by BV 2018(B), 14,831 by AM BV2018 and 1,344,203 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 08, 2021 Filed Sep 8, 2021 23:19 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	18,663	$28.61	$533,948.43	Disclosure SEC source: 0001209191-21-055212 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,903,369 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F9 · shares: The shares were sold as follows: 6,644 by BV 2014, 229 by AM BV2014, 4,196 by BV 2018, 83 by AM BV2018 and 7,511 by UBS Oncology. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.02 to $29.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F11 · ownership.nature: The shares are held as follows: 2,044,070 by BV 2014, 107,713 by BV 2014(B), 70,356 by AM BV2014, 1,290,991 by BV 2018, 54,213 by BV 2018(B), 25,478 by AM BV2018 and 2,310,548 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
September 08, 2021 Filed Sep 8, 2021 22:17 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	10,842	$29.11	$315,610.62	Disclosure SEC source: 0001209191-21-055200 · doc4.xml · nonDerivative · entry 6 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,688,176 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.185 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
September 08, 2021 Filed Sep 8, 2021 22:17 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	1,499	$29.11	$43,635.89	Disclosure SEC source: 0001209191-21-055200 · doc4.xml · nonDerivative · entry 5 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,068 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.185 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
September 07, 2021 Filed Sep 8, 2021 23:19 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	OtherCommon Stock	31,340	$0.00	$0.00	Disclosure SEC source: 0001209191-21-055212 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,922,032 F6 · kind: Represents a pro rata in-kind distribution from BV 2014(B) and BV 2018(B) to its respectve limited partners for no consideration. F7 · shares: The shares were distributed as follows: 20,848 shares by BV 2014(B) and 10,492 shares by BV 2018(B). F8 · ownership.nature: The shares are held as follows: 2,050,714 by BV 2014, 107,713 by BV 2014(B), 70,585 by AM BV2014, 1,295,187 by BV 2018, 54,213 by BV 2018(B), 25,561 by AM BV2018 and 2,318,059 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
September 07, 2021 Filed Sep 8, 2021 23:19 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	50,996	$29.18	$1,488,063.28	Disclosure SEC source: 0001209191-21-055212 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner UBS Oncology Impact Fund L.P. · CIK 0001691428 · 10% owner BioImpact Capital LLC · CIK 0001687078 · 10% owner Oncology Impact Fund (Cayman) Management L.P. · CIK 0001721036 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,953,372 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F2 · shares: The shares were sold as follows: 18,156 by MPM BioVentures 2014, L.P. ("BV 2014"), 625 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 11,467 by MPM BioVentures 2018, L.P. ("BV 2018"), 226 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 20,522 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC. F3 · shares: BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.89 to $29.64 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are held as follows: 2,050,714 by BV 2014, 128,561 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 70,585 by AM BV2014, 1,295,187 by BV 2018, 64,705 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 25,561 by AM BV2018 and 2,318,059 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Read SEC document
September 07, 2021 Filed Sep 8, 2021 22:17 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	25,067	$29.04	$727,945.68	Disclosure SEC source: 0001209191-21-055200 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,699,018 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.22 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
September 07, 2021 Filed Sep 8, 2021 22:17 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	3,465	$29.04	$100,623.60	Disclosure SEC source: 0001209191-21-055200 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,567 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.22 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
September 03, 2021 Filed Sep 8, 2021 22:17 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	12,731	$29.60	$376,837.60	Disclosure SEC source: 0001209191-21-055200 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,724,085 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
September 03, 2021 Filed Sep 8, 2021 22:17 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	1,760	$29.60	$52,096.00	Disclosure SEC source: 0001209191-21-055200 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,032 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
September 02, 2021 Filed Sep 2, 2021 21:25 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	15,757	$29.46	$464,201.22	Disclosure SEC source: 0001209191-21-054517 · doc4.xml · nonDerivative · entry 8 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,736,816 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
September 02, 2021 Filed Sep 2, 2021 21:25 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	2,178	$29.46	$64,163.88	Disclosure SEC source: 0001209191-21-054517 · doc4.xml · nonDerivative · entry 7 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,792 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
September 01, 2021 Filed Sep 2, 2021 21:25 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	5,714	$29.47	$168,391.58	Disclosure SEC source: 0001209191-21-054517 · doc4.xml · nonDerivative · entry 6 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,752,573 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
September 01, 2021 Filed Sep 2, 2021 21:25 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	790	$29.47	$23,281.30	Disclosure SEC source: 0001209191-21-054517 · doc4.xml · nonDerivative · entry 5 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,970 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 31, 2021 Filed Sep 2, 2021 21:25 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	1,553	$30.14	$46,807.42	Disclosure SEC source: 0001209191-21-054517 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,758,287 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.01 to $30.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
August 31, 2021 Filed Sep 2, 2021 21:25 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	215	$30.14	$6,480.10	Disclosure SEC source: 0001209191-21-054517 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,760 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.01 to $30.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 31, 2021 Filed Sep 2, 2021 21:25 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	1,285	$29.43	$37,817.55	Disclosure SEC source: 0001209191-21-054517 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,759,840 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
August 31, 2021 Filed Sep 2, 2021 21:25 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	177	$29.43	$5,209.11	Disclosure SEC source: 0001209191-21-054517 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,975 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 30, 2021 Filed Aug 31, 2021 20:48 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	31,001	$29.30	$908,329.30	Disclosure SEC source: 0001209191-21-054094 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,761,125 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
August 30, 2021 Filed Aug 31, 2021 20:48 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	4,285	$29.30	$125,550.50	Disclosure SEC source: 0001209191-21-054094 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,152 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 27, 2021 Filed Aug 31, 2021 20:48 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	13,357	$29.09	$388,555.13	Disclosure SEC source: 0001209191-21-054094 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,792,126 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.38 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
August 27, 2021 Filed Aug 31, 2021 20:48 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	1,846	$29.09	$53,700.14	Disclosure SEC source: 0001209191-21-054094 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,437 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.38 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 25, 2021 Filed Aug 25, 2021 23:41 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	1,713	$29.09	$49,831.17	Disclosure SEC source: 0001209191-21-053379 · doc4.xml · nonDerivative · entry 6 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,805,483 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.01 to $29.47 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
August 25, 2021 Filed Aug 25, 2021 23:41 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	237	$29.09	$6,894.33	Disclosure SEC source: 0001209191-21-053379 · doc4.xml · nonDerivative · entry 5 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,283 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.01 to $29.47 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 24, 2021 Filed Aug 25, 2021 23:41 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	50,882	$29.48	$1,500,001.36	Disclosure SEC source: 0001209191-21-053379 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,807,196 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.15 to $29.715 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
August 24, 2021 Filed Aug 25, 2021 23:41 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	7,025	$29.48	$207,097.00	Disclosure SEC source: 0001209191-21-053379 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,520 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.15 to $29.715 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 23, 2021 Filed Aug 25, 2021 23:41 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	53,359	$29.11	$1,553,280.49	Disclosure SEC source: 0001209191-21-053379 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,858,018 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.41 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC. F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
August 23, 2021 Filed Aug 25, 2021 23:41 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	7,376	$29.11	$214,715.36	Disclosure SEC source: 0001209191-21-053379 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,545 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.41 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 11, 2021 Filed Aug 12, 2021 20:54 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	2,510	$29.05	$72,915.50	Disclosure SEC source: 0001209191-21-051147 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,911,377 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.13 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC. F4 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein. Read SEC document
August 11, 2021 Filed Aug 12, 2021 20:54 UTC	Cullinan Therapeutics, Inc. CGEM · Entity 4766	SaleCommon Stock	347	$29.05	$10,080.35	Disclosure SEC source: 0001209191-21-051147 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,921 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.13 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
July 12, 2021 Filed Jul 13, 2021 20:21 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	711	$34.10	$24,245.10	Disclosure SEC source: 0001209191-21-046491 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,882,485 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F8 · shares: The shares were sold as follows: 303 by BV 2014, 10 by AM BV2014 and 398 by UBS Oncology. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.055 to $34.135 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F10 · ownership.nature: The shares are held as follows: 2,036,689 by BV 2014, 135,843 by BV 2014(B), 70,104 by AM BV2014 and 1,639,849 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
July 12, 2021 Filed Jul 13, 2021 20:21 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	57,301	$33.58	$1,924,167.58	Disclosure SEC source: 0001209191-21-046491 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,883,196 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F5 · shares: The shares were sold as follows: 24,408 by BV 2014, 838 by AM BV2014 and 32,055 by UBS Oncology. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.05 to $34.04 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: The shares are held as follows: 2,036,992 by BV 2014, 135,843 by BV 2014(B), 70,114 by AM BV2014 and 1,640,247 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
July 09, 2021 Filed Jul 13, 2021 20:21 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	4,067	$33.06	$134,455.02	Disclosure SEC source: 0001209191-21-046491 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,940,497 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F2 · shares: The shares were sold as follows: 1,732 by MPM BioVentures 2014, L.P. ("BV 2014"), 60 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 2,275 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.95 to $33.20 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,061,400 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 70,952 by AM BV2014 and 1,672,302 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Ansbert Gadicke is a managing director of BV LLC. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the Managing Member of Oncology GP LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 29, 2021 Filed Jun 30, 2021 21:25 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	2,700	$33.29	$89,883.00	Disclosure SEC source: 0001209191-21-044004 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,944,564 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F5 · shares: The shares were sold as follows: 1,150 by BV 2014, 40 by AM BV2014 and 1,510 by UBS Oncology. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.95 to $33.78 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F9 · ownership.nature: The shares are held as follows: 2,063,132 by BV 2014, 135,843 by BV 2014(B), 71,012 by AM BV2014 and 1,674,577 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 28, 2021 Filed Jun 30, 2021 21:25 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	2,700	$34.82	$94,014.00	Disclosure SEC source: 0001209191-21-044004 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,947,264 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F5 · shares: The shares were sold as follows: 1,150 by BV 2014, 40 by AM BV2014 and 1,510 by UBS Oncology. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.60 to $35.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: The shares are held as follows: 2,064,282 by BV 2014, 135,843 by BV 2014(B), 71,052 by AM BV2014 and 1,676,087 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 28, 2021 Filed Jun 30, 2021 21:25 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	13,800	$34.06	$470,028.00	Disclosure SEC source: 0001209191-21-044004 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,949,964 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F2 · shares: The shares were sold as follows: 5,878 by MPM BioVentures 2014, L.P. ("BV 2014"), 202 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 7,720 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.59 to $34.54 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,065,432 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 71,092 by AM BV2014 and 1,677,597 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Ansbert Gadicke is a managing director of BV LLC. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the Managing Member of Oncology GP LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 25, 2021 Filed Jun 28, 2021 20:07 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	22,567	$33.51	$756,220.17	Disclosure SEC source: 0001209191-21-043472 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,963,764 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F5 · shares: The shares were sold as follows: 9,612 by BV 2014, 331 by AM BV2014 and 12,624 by UBS Oncology. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.10 to $33.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: The shares are held as follows: 2,071,310 by BV 2014, 135,843 by BV 2014(B), 71,294 by AM BV2014 and 1,685,317 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 24, 2021 Filed Jun 28, 2021 20:07 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	6,121	$33.53	$205,237.13	Disclosure SEC source: 0001209191-21-043472 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,986,331 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F2 · shares: The shares were sold as follows: 2,607 by MPM BioVentures 2014, L.P. ("BV 2014"), 90 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 3,424 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.11 to $33.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,080,922 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 71,625 by AM BV2014 and 1,697,941 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Ansbert Gadicke is a managing director of BV LLC. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the Managing Member of Oncology GP LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 23, 2021 Filed Jun 23, 2021 21:38 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	1,410	$32.98	$46,501.80	Disclosure SEC source: 0001209191-21-042799 · doc4.xml · nonDerivative · entry 5 GADICKE ANSBERT · CIK 0001134655 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,992,452 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F14 · shares: The shares were sold as follows: 601 by BV 2014, 21 by AM BV2014 and 788 by UBS Oncology. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.95 to $33.03 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F16 · ownership.nature: The shares are held as follows: 2,083,529 by BV 2014, 135,843 by BV 2014(B), 71,715 by AM BV2014 and 1,701,365 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 22, 2021 Filed Jun 23, 2021 21:38 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	429	$34.09	$14,624.61	Disclosure SEC source: 0001209191-21-042799 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,993,862 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F11 · shares: The shares were sold as follows: 183 by BV 2014, 6 by AM BV2014 and 240 by UBS Oncology. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.98 to $34.16 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F13 · ownership.nature: The shares are held as follows: 2,084,130 by BV 2014, 135,843 by BV 2014(B), 71,736 by AM BV2014 and 1,702,153 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 22, 2021 Filed Jun 23, 2021 21:38 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	3,371	$33.36	$112,456.56	Disclosure SEC source: 0001209191-21-042799 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,994,291 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F8 · shares: The shares were sold as follows: 1,436 by BV 2014, 50 by AM BV2014 and 1,885 by UBS Oncology. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.95 to $33.93 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F10 · ownership.nature: The shares are held as follows: 2,084,313 by BV 2014, 135,843 by BV 2014(B), 71,742 by AM BV2014 and 1,702,393 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 21, 2021 Filed Jun 23, 2021 21:38 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	31,788	$34.63	$1,100,818.44	Disclosure SEC source: 0001209191-21-042799 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,997,662 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F5 · shares: The shares were sold as follows: 13,540 by BV 2014, 466 by AM BV2014 and 17,782 by UBS Oncology. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.39 to $34.87 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: The shares are held as follows: 2,085,749 by BV 2014, 135,843 by BV 2014(B), 71,792 by AM BV2014 and 1,704,278 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 21, 2021 Filed Jun 23, 2021 21:38 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	5,800	$33.80	$196,040.00	Disclosure SEC source: 0001209191-21-042799 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,029,450 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F2 · shares: The shares were sold as follows: 2,471 by MPM BioVentures 2014, L.P. ("BV 2014"), 85 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 3,244 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.33 to $34.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,099,289 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 72,258 by AM BV2014 and 1,722,060 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Ansbert Gadicke is a managing director of BV LLC. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the Managing Member of Oncology GP LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 18, 2021 Filed Jun 21, 2021 20:06 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	3,199	$34.03	$108,861.97	Disclosure SEC source: 0001209191-21-041944 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,035,250 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F11 · shares: The shares were sold as follows: 1,363 by BV 2014, 47 by AM BV2014 and 1,789 by UBS Oncology. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.97 to $34.14 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F13 · ownership.nature: The shares are held as follows: 2,101,760 by BV 2014, 135,843 by BV 2014(B), 72,343 by AM BV2014 and 1,725,304 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 18, 2021 Filed Jun 21, 2021 20:06 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	5,801	$33.46	$194,101.46	Disclosure SEC source: 0001209191-21-041944 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,038,449 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F8 · shares: The shares were sold as follows: 2,471 by BV 2014, 85 by AM BV2014 and 3,245 by UBS Oncology. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.95 to $33.94 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F10 · ownership.nature: The shares are held as follows: 2,103,123 by BV 2014, 135,843 by BV 2014(B), 72,390 by AM BV2014 and 1,727,093 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 17, 2021 Filed Jun 21, 2021 20:06 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	1,708	$34.12	$58,276.96	Disclosure SEC source: 0001209191-21-041944 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,044,250 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F5 · shares: The shares were sold as follows: 728 by BV 2014, 25 by AM BV2014 and 955 by UBS Oncology. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.07 to $34.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: The shares are held as follows: 2,105,594 by BV 2014, 135,843 by BV 2014(B), 72,475 by AM BV2014 and 1,730,338 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 17, 2021 Filed Jun 21, 2021 20:06 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	30,810	$33.78	$1,040,761.80	Disclosure SEC source: 0001209191-21-041944 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,045,958 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F2 · shares: The shares were sold as follows: 13,123 by MPM BioVentures 2014, L.P. ("BV 2014"), 452 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 17,235 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.06 to $34.03 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,106,322 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 72,500 by AM BV2014 and 1,731,293 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Ansbert Gadicke is a managing director of BV LLC. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the Managing Member of Oncology GP LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 16, 2021 Filed Jun 16, 2021 21:09 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	4,227	$33.33	$140,885.91	Disclosure SEC source: 0001209191-21-040961 · doc4.xml · nonDerivative · entry 2 GADICKE ANSBERT · CIK 0001134655 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,076,768 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F5 · shares: The shares were sold as follows: 1,800 by BV 2014, 62 by AM BV2014 and 2,365 by UBS Oncology. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.95 to $33.66 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: The shares are held as follows: 2,119,445 by BV 2014, 135,843 by BV 2014(B), 72,952 by AM BV2014 and 1,748,528 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 14, 2021 Filed Jun 16, 2021 21:09 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	2,000	$33.09	$66,180.00	Disclosure SEC source: 0001209191-21-040961 · doc4.xml · nonDerivative · entry 1 GADICKE ANSBERT · CIK 0001134655 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,080,995 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F2 · shares: The shares were sold as follows: 852 by MPM BioVentures 2014, L.P. ("BV 2014"), 29 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 1,119 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.95 to $33.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,121,245 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 73,014 by AM BV2014 and 1,750,893 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Ansbert Gadicke is a managing director of BV LLC. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the Managing Member of Oncology GP LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 09, 2021 Filed Jun 10, 2021 20:04 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	24,368	$34.79	$847,762.72	Disclosure SEC source: 0001209191-21-039425 · doc4.xml · nonDerivative · entry 4 GADICKE ANSBERT · CIK 0001134655 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,082,995 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F11 · shares: The shares were sold as follows: 10,379 by BV 2014, 359 by AM BV2014 and 13,630 by UBS Oncology. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.69 to $35.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F13 · ownership.nature: The shares are held as follows: 2,122,097 by BV 2014, 135,843 by BV 2014(B), 73,043 by AM BV2014 and 1,752,012 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 09, 2021 Filed Jun 10, 2021 20:04 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	10,862	$34.42	$373,870.04	Disclosure SEC source: 0001209191-21-039425 · doc4.xml · nonDerivative · entry 3 GADICKE ANSBERT · CIK 0001134655 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,107,363 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F8 · shares: The shares were sold as follows: 4,627 by BV 2014, 158 by AM BV2014 and 6,077 by UBS Oncology. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.66 to $34.65 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F10 · ownership.nature: The shares are held as follows: 2,132,476 by BV 2014, 135,843 by BV 2014(B), 73,402 by AM BV2014 and 1,765,642 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.